Pancreatic Cancer

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer

Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer

By

Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.

Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer

Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer

By

The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.

Pancreatic Tumor Bacteria Found To Be Similar to Microbes Located in the Mouth

Pancreatic Tumor Bacteria Found To Be Similar to Microbes Located in the Mouth

By

The bacterial strains found in oral samples may be representative of the types of strains that exist in the tumor microbiomes of patients with pancreatic or GI disease.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer

Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer

By

Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.

<i>KRAS</i> Mutations May Influence Location, Local Recurrence of Resected Pancreatic Cancer

KRAS Mutations May Influence Location, Local Recurrence of Resected Pancreatic Cancer

By

Different KRAS mutations may be associated with differing primary tumor locations and patterns of local recurrence in resected pancreatic cancer.

Pancreatic Cancer Risk Linked to Number of First-Degree Relatives Who Are Affected by Cancer

Pancreatic Cancer Risk Linked to Number of First-Degree Relatives Who Are Affected by Cancer

By

Pancreatic risk rises in a dose-response manner with increasing number of affected first-degree relatives.

New Molecular Features May Provide Insight Into Primary Pancreatic Cancer

New Molecular Features May Provide Insight Into Primary Pancreatic Cancer

By

Molecular features of primary and metastatic PDAC may provide new insight into disease management and drug development.

Characterization of Tumor Stromal Cells at the Single-Cell Level Using Machine Learning

Characterization of Tumor Stromal Cells at the Single-Cell Level Using Machine Learning

By

Researchers describe SuperCT, a predictive framework for the identification of tumor stromal cell type based on scRNA-seq data.

New-Onset Diabetes Associated With IPMN Progression

New-Onset Diabetes Associated With IPMN Progression

By

New-onset diabetes, but not baseline diabetes, is associated with an increased risk of progression of intraductal papillary mucinous neoplasms.

Pancreatic Cancer Organoids May Be a Platform to Study Response to Immunotherapies

Pancreatic Cancer Organoids May Be a Platform to Study Response to Immunotherapies

By

Organoids propagated from pancreatic tumor cells may provide a platform to evaluate patient response to immune checkpoint inhibitors.

Moffitt's Basal-Like Gene Signature Associated With Poor Survival in Pancreatic Cancer

Moffitt's Basal-Like Gene Signature Associated With Poor Survival in Pancreatic Cancer

By

The Moffitt gene set identifies a poor prognostic group of patients with locally advanced or metastatic pancreatic cancer.

Pancreatic Cancer CTCs Harvested by Leukapheresis Yield Organoids

Pancreatic Cancer CTCs Harvested by Leukapheresis Yield Organoids

By

Organoids can be propagated from CTCs from patients with pancreatic cancer, potentially offering an approach to study treatment resistance.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

BRCA Status Could Inform Pancreatic Cancer Management

BRCA Status Could Inform Pancreatic Cancer Management

By

The development of BRCA-targeted therapies might offer the best opportunities to bring pancreatic cancer into the precision-oncology era.

Hepatitis B Infection May Increase the Risk for Pancreatic Cancer

Hepatitis B Infection May Increase the Risk for Pancreatic Cancer

Investigators assessed the association of hepatitis B infection and pancreatic cancer, along with predictors of pancreatic cancer and mortality.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Pancreatic Cancer and New-Onset Diabetes

Pancreatic Cancer and New-Onset Diabetes

By

New-onset adult diabetes mellitus appears to be both a risk factor for and a sequelae of pancreatic cancer.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling

Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling

By

Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs